pyrazines has been researched along with Dyslipidemias in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, Y; Chen, Y; Li, J; Li, L; Li, Y; Wang, H; Wang, Q; Yang, D; Yu, B; Zhai, J; Zhang, H; Zhang, P; Zhao, X | 1 |
| Cicalini, S; D'Abbraccio, M; d'Ettorre, G; Di Biagio, A; Maggi, P; Martinelli, C; Nunnari, G; Rusconi, S; Sighinolfi, L; Spagnuolo, V; Squillace, N | 1 |
| Anderson, MS; Engel, SS; Hanson, ME; Musliner, T; Steinberg, H | 1 |
| Guan, M; Li, C; Li, J; Lyv, F; Wang, C; Xue, Y; Zeng, Y; Zheng, Z | 1 |
| Charest, A; Couture, P; Droit, A; Kelly, I; Lamarche, B; Lépine, MC; Tremblay, AJ | 1 |
| Sekhar, RV | 1 |
| Chen, S; Jiang, F; Liu, C; Qian, J; Zhang, W | 1 |
| Feng, Y; Howard, AD; Li, C; Li, Z; Moller, DE; Mu, J; Roy, RS; Thornberry, NA; Woods, J; Zhang, BB; Zhou, YP; Zhu, L; Zycband, E | 1 |
3 review(s) available for pyrazines and Dyslipidemias
| Article | Year |
|---|---|
Cardiovascular risk and dyslipidemia among persons living with HIV: a review.
Topics: Anti-HIV Agents; Cardiovascular Diseases; Cholesterol; Dyslipidemias; Growth Hormone-Releasing Hormone; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipodystrophy; Pyrazines; Risk Factors | 2017 |
Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin.
Topics: Biomarkers; Blood Glucose; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Lipids; Pyrazines; Simvastatin; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2013 |
Treatment of dyslipidemia in HIV.
Topics: Anti-HIV Agents; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Diet Therapy; Dyslipidemias; Exercise Therapy; Ezetimibe; Fatty Acids, Nonesterified; Fatty Acids, Omega-3; Fibric Acids; Glutathione; Growth Hormone-Releasing Hormone; HIV Infections; Human Growth Hormone; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leptin; Niacin; Pyrazines; Thiazolidinediones; Triglycerides | 2015 |
2 trial(s) available for pyrazines and Dyslipidemias
| Article | Year |
|---|---|
Effect of DLT-SML on Chronic Stable Angina Through Ameliorating Inflammation, Correcting Dyslipidemia, and Regulating Gut Microbiota.
Topics: Adult; Aged; Angina, Stable; Anti-Inflammatory Agents; Bacteria; Biomarkers; China; Cytokines; Drug Therapy, Combination; Drugs, Chinese Herbal; Dysbiosis; Dyslipidemias; Female; Gastrointestinal Microbiome; Humans; Hypolipidemic Agents; Inflammation; Inflammation Mediators; Lipids; Male; Methylamines; Middle Aged; Pyrazines; Time Factors; Treatment Outcome | 2021 |
Effect of sitagliptin therapy on triglyceride-rich lipoprotein kinetics in patients with type 2 diabetes.
Topics: Apolipoprotein B-48; Apolipoproteins; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Dyslipidemias; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Triglycerides | 2014 |
3 other study(ies) available for pyrazines and Dyslipidemias
| Article | Year |
|---|---|
The dipeptidyl peptidase-4 inhibitor sitagliptin protects against dyslipidemia-related kidney injury in Apolipoprotein E knockout mice.
Topics: Acute Kidney Injury; AMP-Activated Protein Kinases; Animals; Apolipoproteins E; Dipeptidyl-Peptidase IV Inhibitors; Dyslipidemias; Fibronectins; Kidney; Male; Mice; Mice, Inbred C57BL; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; Sitagliptin Phosphate; Transforming Growth Factor beta1; Triazoles | 2014 |
Ligustrazine improves atherosclerosis in rat via attenuation of oxidative stress.
Topics: Animals; Antioxidants; Aorta, Thoracic; Atherosclerosis; Cholesterol; Diet, Atherogenic; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Dyslipidemias; Ligusticum; Lipid Metabolism; Liver; Liver Function Tests; Male; Oxidative Stress; Phytotherapy; Pyrazines; Rats; Rats, Sprague-Dawley; Rhizome; Triglycerides; Vasodilator Agents | 2011 |
Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Disease Models, Animal; Dyslipidemias; Glipizide; Hypoglycemic Agents; Immunohistochemistry; Insulin; Insulin-Secreting Cells; Islets of Langerhans; Male; Mice; Mice, Inbred ICR; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles | 2006 |